Abstract CT255: AdvanTIG-204: A Phase 2, Multicenter, Randomized, 3-Arm, Open-Label Study Investigating the Preliminary Efficacy and Safety of Ociperlimab (Anti-Tigit) + Tislelizumab (Anti-Pd-1) + Concurrent Chemoradiotherapy (ccrt) in Patients with Untreated Limited-Stage Small Cell Lung Cancer (SCLC)
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined